GRAIL, Inc. (GRAL) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2026. GRAIL, Inc. is a commercial-stage healthcare company focused on multi-cancer early detection (MCED) via its Galleri blood test. The company operates as a single reportable segment. As of June 30, 2026, the company had 44,666,234 shares of common stock outstanding. The company is classified as an emerging growth company and a non-accelerated filer.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Total Revenue | $44,687 | $35,544 | $85,472 | $67,381 |
| Net Loss | $(110,247) | $(113,985) | $(203,434) | $(220,198) |
| Loss Per Share (Basic/Diluted) | $(2.56) | $(3.18) | $(4.86) | $(6.28) |
| Adjusted EBITDA | $(90,270) | $(78,322) | $(170,192) | $(177,057) |
| Cash & Cash Equivalents | $55,645 | $127,427 | $55,645 | $127,427 |
| Short-term Marketable Securities | $805,964 | $654,703 | $805,964 | $654,703 |
| Total Liquidity | $861,609 | $782,130 | $861,609 | $782,130 |
| Net Cash Used in Operating Activities (YTD) | $(167,719) | $(171,977) | $(167,719) | $(171,977) |
Note: Financial results are significantly impacted by pushdown accounting, including amortization of intangible assets ($33.5M for Q2) and impairment charges.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 26% year-over-year (Q2) and 27% year-over-year (YTD). Screening revenue grew 24% in Q2, driven by a 35% increase in Galleri sales volume, partially offset by an 8% decrease in average selling price (ASP).
- Expense Increases: Sales and marketing expenses rose 32% in Q2 due to commercial ramp-up and headcount increases. General and administrative expenses increased 34% in Q2, driven by higher compensation and legal/professional fees related to FDA approval efforts.
- Impairment Charges: The company recognized a $25.4 million impairment charge in Q2 2026 related to the deferred asset from the Samsung Stock Purchase Agreement (SPA). This compares to a $28.0 million impairment in Q2 2025 related to in-process research and development.
- Capital Raise: In June 2026, the company completed a private placement with Samsung investors, issuing 1,570,308 shares for gross proceeds of approximately $110 million.
- Leadership Change: Dr. Joshua Ofman was appointed CEO effective June 1, 2026, leading to a revision in internal management reporting and segment expense presentation.
Guidance, Outlook, and Risks
- Regulatory Pathway: GRAIL submitted a Premarket Approval (PMA) application to the FDA in January 2026. The FDA Molecular and Clinical Genetics Panel is expected to review the PMA in the fall of 2026. FDA approval is viewed as critical for unlocking broader commercial payor coverage.
- Clinical Trial Results: The company presented results from the NHS-Galleri Trial and PATHFINDER 2 study. While the NHS-Galleri Trial did not meet its primary endpoint of statistically significant combined Stage 3 and 4 reduction, it demonstrated a substantial reduction in Stage 4 diagnoses and increased early-stage detection. These results triggered a decline in market capitalization and subsequent securities litigation.
- Liquidity: Management believes existing cash, cash equivalents, and short-term marketable securities ($861.6 million total) are sufficient to meet working capital needs for at least the next 12 months.
- Risks:
- Legal Proceedings: New securities class action lawsuits were filed in June 2026 alleging false statements regarding the NHS-Galleri Trial results. Existing litigation regarding the Illumina acquisition continues.
- Reimbursement: Galleri is not currently broadly reimbursed by Medicare or large commercial insurers. Adoption depends on FDA approval and potential inclusion in USPSTF guidelines.
- Competition: New MCED products entered the market in late 2025, increasing competitive pressure.
Key Facts for Investor Verification
- Impairment Specifics: Verify the recoverability assessment methodology used for the $25.4 million Samsung SPA deferred asset impairment and the impact on future revenue recognition from the Samsung collaboration.
- Regulatory Timeline: Monitor the FDA Advisory Committee meeting date and recommendation regarding the Galleri PMA application scheduled for fall 2026.
- Litigation Exposure: Assess the potential financial impact of the new securities class actions filed in June 2026 related to the NHS-Galleri Trial disclosures.
- Revenue Mix: Track the trend in Average Selling Price (ASP) and the proportion of revenue from government vs. commercial sources, as ASP decreased 8% in Q2 2026.
- Royalty Obligations: Note that royalty payments to Illumina are suspended until December 24, 2026; verify the impact on margins once this suspension lifts.